TABLE 1.
Demographic features, clinical characteristics, and patient‐reported outcomes for 1258, 1217, and 1653 male germ cell tumor survivors included in studies for cisplatin‐induced hearing loss, tinnitus, and peripheral neuropathy
| Characteristic | Hearing loss a | Tinnitus b | Peripheral sensory neuropathy c | |||||
|---|---|---|---|---|---|---|---|---|
| All survivors | No (Controls) | Yes (Cases) | All survivors | None | Mild | Severe | ||
| n | 1258 | 1217 | 979 | 238 | 1653 | 704 | 740 | 209 |
| Age at last observation, year, Median (range) | 37 (18–74) | 37 (18–75) | 36 (18–75) | 40 (18–74) | 37 (18–75) | 34 (18–72) | 38 (18–75) | 41 (20–65) |
| Age at testicular cancer diagnosis, year, Median (range) | 31 (10–60) | 30 (10–60) | 30 (10–60) | 32 (10–55) | 30 (10–60) | 28 (10–54) | 32 (10–60) | 34 (13–55) |
| Time since therapy completion, year, Median (range) | 4 (0–37) | 4 (0–37) | 4 (0–37) | 4 (0–35) | 4 (0–37) | 4 (0–37) | 4 (0–35) | 4 (0–37) |
| BMI at evaluation, kg/m2, Median (range) | 27 (18–67) | 27 (18–67) | 27 (18–60) | 28 (18–67) | 27 (18–67) | 27 (18–66) | 27 (18–54) | 29 (18–67) |
| Hearing thresholds, dB, Median (range) a | 18 (1–96) | 18 (1–96) | 15 (1–93) | 38 (2–96) | 18 (1–96) | 15 (1–93) | 20 (2–94) | 28 (1–96) |
| Chemotherapy regimen d | ||||||||
| BEP | 696 (55.3) | 662 (54.5) | 534 (54.7) | 128 (53.8) | 897 (54.4) | 370 (52.7) | 431 (58.2) | 96 (45.9) |
| EP | 458 (36.4) | 462 (38.0) | 372 (38.1) | 90 (37.8) | 623 (37.7) | 271 (38.6) | 261 (35.3) | 91 (43.5) |
| VIP | 30 (2.4) | 20 (1.6) | 13 (1.3) | 7 (2.9) | 35 (2.1) | 12 (1.7) | 17 (2.3) | 6 (2.9) |
| VeIP | 1 (0.1) | 2 (0.2) | 2 (0.2) | 0 (0.0) | 2 (0.1) | 2 (0.3) | 0 (0.0) | 0 (0.0) |
| PVB | 3 (0.2) | 2 (0.2) | 1 (0.1) | 1 (0.4) | 4 (0.2) | 1 (0.1) | 2 (0.3) | 1 (0.5) |
| Other | 70 (5.6) | 67 (5.5) | 55 (5.6) | 12 (5.0) | 90 (5.5) | 46 (6.5) | 29 (3.9) | 15 (7.2) |
| Cumulative dose of cisplatin, mg/m 2 e | ||||||||
| Median(range) | 400 (100–1000) | 400 (100–1000) | 400 (130–1000) | 400 (100–800) | 400 (100–1000) | 400 (190–600) | ||
| <300 | 59 (4.7) | 82 (6.8) | 68 (7.0) | 14 (5.9) | 102 (6.2) | 41 (5.9) | 50 (6.8) | 11 (5.3) |
| 300 | 468 (37.4) | 440 (36.5) | 366 (37.8) | 74 (31.1) | 592 (36.1) | 272 (39.1) | 271 (36.7) | 49 (23.5) |
| >300 and < 400 | 50 (4.0) | 42 (3.5) | 31 (3.2) | 11 (4.6) | 66 (4.0) | 23 (3.3) | 36 (4.9) | 7 (3.4) |
| 400 | 618 (49.5) | 579 (48.0) | 467 (48.3) | 112 (47.1) | 793 (48.3) | 318 (45.8) | 350 (47.4) | 125 (60.1) |
| >400 | 55 (4.4) | 63 (5.2) | 36 (3.7) | 27 (11.3) | 88 (5.4) | 41 (5.9) | 31 (4.2) | 16 (7.7) |
| Persistent dizziness/vertigo f | ||||||||
| Yes | 53 (4.5) | 53 (4.6) | 23 (2.4) | 30 (14.4) | 71 (4.6) | 12 (1.8) | 35 (5.1) | 24 (12.8) |
| No | 1125 (95.5) | 1104 (95.4 | 926 (97.6) | 178 (85.6) | 1487 (95.4) | 665 (98.2) | 658 (94.9) | 164 (87.2) |
| Self‐reported health g | ||||||||
| Excellent | 210 (16.9) | 194 (16.0) | 172 (17.7) | 22 (9.3) | 268 (16.3) | 145 (20.7) | 107 (14.5) | 16 (7.7) |
| Very good | 524 (42.2) | 502 (41.4) | 432 (44.4) | 70 (29.4) | 670 (40.7) | 313 (44.7) | 306 (41.4) | 51 (24.5) |
| Good | 419 (33.7) | 421 (34.8) | 315 (32.3) | 106 (44.5) | 582 (35.3) | 214 (30.6) | 269 (36.4) | 99 (47.6) |
| Poor/fair | 90 (7.2) | 95 (7.8) | 55 (5.6) | 40 (16.8) | 127 (7.7) | 28 (4.0) | 57 (7.7) | 42 (20.2) |
| Hypertension and on medication h | ||||||||
| Yes | 142 (11.8) | 136 (11.7) | 85 (9.1) | 51 (22.8) | 189 (12.0) | 47 (6.9) | 96 (13.7) | 46 (23.6) |
| No | 1057 (88.2) | 1023 (88.3) | 850 (90.9) | 173 (77.2) | 1390 (88.0) | 634 (93.1) | 607 (86.3) | 149 (76.4) |
| Hypercholesterolemia and on medication i | ||||||||
| Yes | 131 (10.9) | 131 (11.2) | 90 (9.5) | 41 (18.5) | 166 (10.4) | 55 (7.9) | 81 (11.4) | 30 (15.6) |
| No | 1072 (89.1) | 1040 (88.8) | 859 (90.5) | 181 (81.5) | 1426 (89.6) | 637 (92.1) | 627 (88.6) | 162 (84.4) |
Note: Data presented as number (%) unless otherwise noted.
Abbreviations: BMI, body mass index; BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and cisplatin; VIP, cisplatin, etoposide, and ifosfamide; VeIP, cisplatin, vinblastine, and ifosfamide; PVB, cisplatin, bleomycin, and maintenance vinblastine.
One thousand two hundred and fifty‐eight patients were included with quantitative values modeled using the geometric mean of bilateral average air conduction thresholds measured at frequencies between 4 and 12 kHz as described previously. 10 , 11
Tinnitus phenotype excludes 463 participants who did not answer‐related questions. Cases are restricted to survivors who reported “quite a bit” or “very much” tinnitus. Survivors who reported “a little” tinnitus (n = 426) are excluded from the table and all analyses.
Following conversion of the Likert scale: “none, a little, quite a bit, very much” to a 0–3 numeric scale, we created four categories to represent the severity of peripheral neuropathy using a summary statistic and combined groups 2 and 3. 13 Phenotype excludes 27 participants for whom the variables were not stated.
BEP category includes survivors who received only bleomycin, etoposide, and cisplatin; EP includes survivors who received only etoposide and cisplatin. VIP includes survivors who received only cisplatin, etoposide, and ifosfamide; VeIP includes survivors who received only cisplatin, vinblastine, and ifosfamide; PVB includes survivors who received only cisplatin, bleomycin, and maintenance vinblastine. Both tinnitus and peripheral sensory neuropathy had two survivors with missing dose data.
Category excludes eight participants with incomplete dose data for hearing loss, 11 for tinnitus, and 12 for peripheral neuropathy.
Persistent vertigo or dizziness status was not stated for 80 hearing loss participants, 60 tinnitus participants, and 95 peripheral sensory neuropathy participants.
Self‐reported health status was not stated for 15 hearing loss participants, five tinnitus participants, and six peripheral sensory neuropathy participants.
Hypertension status was not stated for 59 participants with hearing loss, 58 participants with tinnitus, and 74 participants with peripheral sensory neuropathy.